ID   DPOD3_HUMAN             Reviewed;         466 AA.
AC   Q15054; B7ZAI6; Q32MZ9; Q32N00;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   26-SEP-2001, sequence version 2.
DT   10-MAY-2017, entry version 153.
DE   RecName: Full=DNA polymerase delta subunit 3;
DE   AltName: Full=DNA polymerase delta subunit C {ECO:0000303|PubMed:11595739};
DE   AltName: Full=DNA polymerase delta subunit p66;
DE   AltName: Full=DNA polymerase delta subunit p68 {ECO:0000303|PubMed:22148433, ECO:0000303|PubMed:22801543};
GN   Name=POLD3; Synonyms=KIAA0039;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Bone marrow;
RX   PubMed=7584026; DOI=10.1093/dnares/1.1.27;
RA   Nomura N., Miyajima N., Sazuka T., Tanaka A., Kawarabayasi Y.,
RA   Sato S., Nagase T., Seki N., Ishikawa K., Tabata S.;
RT   "Prediction of the coding sequences of unidentified human genes. I.
RT   The coding sequences of 40 new genes (KIAA0001-KIAA0040) deduced by
RT   analysis of randomly sampled cDNA clones from human immature myeloid
RT   cell line KG-1.";
RL   DNA Res. 1:27-35(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 2-19 AND 110-123, CLEAVAGE OF INITIATOR
RP   METHIONINE, ACETYLATION AT ALA-2, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RA   Bienvenut W.V., Waridel P., Quadroni M.;
RL   Submitted (MAR-2009) to UniProtKB.
RN   [7]
RP   FUNCTION.
RX   PubMed=10219083; DOI=10.1093/nar/27.10.2108;
RA   Hughes P., Tratner I., Ducoux M., Piard K., Baldacci G.;
RT   "Isolation and identification of the third subunit of mammalian DNA
RT   polymerase delta by PCNA-affinity chromatography of mouse FM3A cell
RT   extracts.";
RL   Nucleic Acids Res. 27:2108-2114(1999).
RN   [8]
RP   FUNCTION.
RX   PubMed=10852724; DOI=10.1021/bi0000871;
RA   Mo J.-Y., Liu L., Leon A., Mazloum N., Lee M.Y.W.T.;
RT   "Evidence that DNA polymerase delta isolated by immunoaffinity
RT   chromatography exhibits high-molecular weight characteristics and is
RT   associated with the KIAA0039 protein and RPA.";
RL   Biochemistry 39:7245-7254(2000).
RN   [9]
RP   IDENTIFICATION IN POL-DELTA COMPLEX, AND INTERACTION WITH POLD2 AND
RP   PCNA.
RX   PubMed=11328591; DOI=10.1093/oxfordjournals.jbchem.a002909;
RA   Shikata K., Ohta S., Yamada K., Obuse C., Yoshikawa H., Tsurimoto T.;
RT   "The human homologue of fission Yeast cdc27, p66, is a component of
RT   active human DNA polymerase delta.";
RL   J. Biochem. 129:699-708(2001).
RN   [10]
RP   FUNCTION, INTERACTION WITH PCNA AND POLD1, SUBCELLULAR LOCATION, AND
RP   PHOSPHORYLATION.
RX   PubMed=11595739; DOI=10.1074/jbc.M106990200;
RA   Ducoux M., Urbach S., Baldacci G., Huebscher U., Koundrioukoff S.,
RA   Christensen J., Hughes P.;
RT   "Mediation of proliferating cell nuclear antigen (PCNA)-dependent DNA
RT   replication through a conserved p21(Cip1)-like PCNA-binding motif
RT   present in the third subunit of human DNA polymerase delta.";
RL   J. Biol. Chem. 276:49258-49266(2001).
RN   [11]
RP   INTERACTION WITH PCNA, AND CHARACTERIZATION OF POL-DELTA2 AND
RP   POL-DELTA4 COMPLEXES.
RX   PubMed=12403614; DOI=10.1021/bi0262707;
RA   Xie B., Mazloum N., Liu L., Rahmeh A., Li H., Lee M.Y.;
RT   "Reconstitution and characterization of the human DNA polymerase delta
RT   four-subunit holoenzyme.";
RL   Biochemistry 41:13133-13142(2002).
RN   [12]
RP   INTERACTION WITH POLDIP2.
RX   PubMed=12522211; DOI=10.1074/jbc.M208694200;
RA   Liu L., Rodriguez-Belmonte E.M., Mazloum N., Xie B., Lee M.Y.W.T.;
RT   "Identification of a novel protein, PDIP38, that interacts with the
RT   p50 subunit of DNA polymerase delta and proliferating cell nuclear
RT   antigen.";
RL   J. Biol. Chem. 278:10041-10047(2003).
RN   [13]
RP   UBIQUITINATION, SUMOYLATION AT LYS-258 AND LYS-433, AND MUTAGENESIS OF
RP   LYS-258; LYS-325 AND LYS-433.
RX   PubMed=16934752; DOI=10.1016/j.bbrc.2006.08.049;
RA   Liu G., Warbrick E.;
RT   "The p66 and p12 subunits of DNA polymerase delta are modified by
RT   ubiquitin and ubiquitin-like proteins.";
RL   Biochem. Biophys. Res. Commun. 349:360-366(2006).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-307, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [15]
RP   FUNCTION, AND INTERACTION WITH POLD2 AND PCNA.
RX   PubMed=16510448; DOI=10.1074/jbc.M600322200;
RA   Li H., Xie B., Zhou Y., Rahmeh A., Trusa S., Zhang S., Gao Y.,
RA   Lee E.Y., Lee M.Y.;
RT   "Functional roles of p12, the fourth subunit of human DNA polymerase
RT   delta.";
RL   J. Biol. Chem. 281:14748-14755(2006).
RN   [16]
RP   IDENTIFICATION IN POL-DELTA COMPLEX.
RX   PubMed=17317665; DOI=10.1074/jbc.M610356200;
RA   Zhang S., Zhou Y., Trusa S., Meng X., Lee E.Y., Lee M.Y.;
RT   "A novel DNA damage response: rapid degradation of the p12 subunit of
RT   dna polymerase delta.";
RL   J. Biol. Chem. 282:15330-15340(2007).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-307, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-307; SER-407; SER-409;
RP   THR-411; SER-413 AND SER-458, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-307, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [21]
RP   FUNCTION, AND COMPARISON BETWEEN POL-DELTA3 AND POL-DELTA4.
RX   PubMed=19074196; DOI=10.1093/nar/gkn1000;
RA   Meng X., Zhou Y., Zhang S., Lee E.Y., Frick D.N., Lee M.Y.;
RT   "DNA damage alters DNA polymerase delta to a form that exhibits
RT   increased discrimination against modified template bases and
RT   mismatched primers.";
RL   Nucleic Acids Res. 37:647-657(2009).
RN   [22]
RP   FUNCTION, AND IDENTIFICATION IN POL-DELTA COMPLEX.
RX   PubMed=20334433; DOI=10.1021/bi100042b;
RA   Meng X., Zhou Y., Lee E.Y., Lee M.Y., Frick D.N.;
RT   "The p12 subunit of human polymerase delta modulates the rate and
RT   fidelity of DNA synthesis.";
RL   Biochemistry 49:3545-3554(2010).
RN   [23]
RP   FUNCTION IN NUCLEOTIDE EXCISION REPAIR, AND SUBCELLULAR LOCATION.
RX   PubMed=20227374; DOI=10.1016/j.molcel.2010.02.009;
RA   Ogi T., Limsirichaikul S., Overmeer R.M., Volker M., Takenaka K.,
RA   Cloney R., Nakazawa Y., Niimi A., Miki Y., Jaspers N.G.,
RA   Mullenders L.H., Yamashita S., Fousteri M.I., Lehmann A.R.;
RT   "Three DNA polymerases, recruited by different mechanisms, carry out
RT   NER repair synthesis in human cells.";
RL   Mol. Cell 37:714-727(2010).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-307, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-307, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [27]
RP   INTERACTION WITH PCNA, PHOSPHORYLATION AT SER-458, AND MUTAGENESIS OF
RP   456-GLN--LYS-466; SER-458 AND 459-ILE--PHE-463.
RX   PubMed=22148433; DOI=10.1021/bi201638e;
RA   Rahmeh A.A., Zhou Y., Xie B., Li H., Lee E.Y., Lee M.Y.;
RT   "Phosphorylation of the p68 subunit of Pol delta acts as a molecular
RT   switch to regulate its interaction with PCNA.";
RL   Biochemistry 51:416-424(2012).
RN   [28]
RP   SUBCELLULAR LOCATION, IDENTIFICATION IN POL-DELTA COMPLEX, AND
RP   DEVELOPMENTAL STAGE.
RX   PubMed=22801543; DOI=10.4161/cc.21280;
RA   Chea J., Zhang S., Zhao H., Zhang Z., Lee E.Y., Darzynkiewicz Z.,
RA   Lee M.Y.;
RT   "Spatiotemporal recruitment of human DNA polymerase delta to sites of
RT   UV damage.";
RL   Cell Cycle 11:2885-2895(2012).
RN   [29]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [30]
RP   FUNCTION IN OKAZAKI FRAGMENT PROCESSING.
RX   PubMed=24035200; DOI=10.1016/j.dnarep.2013.08.008;
RA   Lin S.H., Wang X., Zhang S., Zhang Z., Lee E.Y., Lee M.Y.;
RT   "Dynamics of enzymatic interactions during short flap human Okazaki
RT   fragment processing by two forms of human DNA polymerase delta.";
RL   DNA Repair 12:922-935(2013).
RN   [31]
RP   POL-DELTA3 COMPLEX EXPRESSION DURING CELL CYCLE.
RX   PubMed=23913683; DOI=10.1074/jbc.M113.490466;
RA   Zhang S., Zhao H., Darzynkiewicz Z., Zhou P., Zhang Z., Lee E.Y.,
RA   Lee M.Y.;
RT   "A novel function of CRL4(Cdt2): regulation of the subunit structure
RT   of DNA polymerase delta in response to DNA damage and during the S
RT   phase.";
RL   J. Biol. Chem. 288:29550-29561(2013).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-277; SER-307 AND
RP   SER-458, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [33]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-258, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [34]
RP   FUNCTION IN TLS, AND IDENTIFICATION IN COMPLEX WITH REV3L; MAD2L2 AND
RP   POLD2.
RX   PubMed=24449906; DOI=10.1073/pnas.1324001111;
RA   Lee Y.S., Gregory M.T., Yang W.;
RT   "Human Pol zeta purified with accessory subunits is active in
RT   translesion DNA synthesis and complements Pol eta in cisplatin
RT   bypass.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:2954-2959(2014).
RN   [35]
RP   FUNCTION IN BIR.
RX   PubMed=24310611; DOI=10.1126/science.1243211;
RA   Costantino L., Sotiriou S.K., Rantala J.K., Magin S., Mladenov E.,
RA   Helleday T., Haber J.E., Iliakis G., Kallioniemi O.P.,
RA   Halazonetis T.D.;
RT   "Break-induced replication repair of damaged forks induces genomic
RT   duplications in human cells.";
RL   Science 343:88-91(2014).
RN   [36]
RP   FUNCTION IN TLS.
RX   PubMed=25628356; DOI=10.1093/nar/gkv023;
RA   Hirota K., Yoshikiyo K., Guilbaud G., Tsurimoto T., Murai J.,
RA   Tsuda M., Phillips L.G., Narita T., Nishihara K., Kobayashi K.,
RA   Yamada K., Nakamura J., Pommier Y., Lehmann A., Sale J.E., Takeda S.;
RT   "The POLD3 subunit of DNA polymerase delta can promote translesion
RT   synthesis independently of DNA polymerase zeta.";
RL   Nucleic Acids Res. 43:1671-1683(2015).
RN   [37]
RP   FUNCTION IN TLS.
RX   PubMed=27185888; DOI=10.1093/nar/gkw439;
RA   Hirota K., Tsuda M., Mohiuddin M., Tsurimoto T., Cohen I.S.,
RA   Livneh Z., Kobayashi K., Narita T., Nishihara K., Murai J., Iwai S.,
RA   Guilbaud G., Sale J.E., Takeda S.;
RT   "In vivo evidence for translesion synthesis by the replicative DNA
RT   polymerase delta.";
RL   Nucleic Acids Res. 44:7242-7250(2016).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 1-144 IN COMPLEX WITH POLD2,
RP   AND INTERACTION WITH POLD2.
RX   PubMed=18818516; DOI=10.4161/cc.7.19.6720;
RA   Baranovskiy A.G., Babayeva N.D., Liston V.G., Rogozin I.B.,
RA   Koonin E.V., Pavlov Y.I., Vassylyev D.G., Tahirov T.H.;
RT   "X-ray structure of the complex of regulatory subunits of human DNA
RT   polymerase delta.";
RL   Cell Cycle 7:3026-3036(2008).
RN   [39]
RP   VARIANTS VAL-194 AND LEU-195.
RX   PubMed=21248752; DOI=10.1038/nature09639;
RA   Varela I., Tarpey P., Raine K., Huang D., Ong C.K., Stephens P.,
RA   Davies H., Jones D., Lin M.L., Teague J., Bignell G., Butler A.,
RA   Cho J., Dalgliesh G.L., Galappaththige D., Greenman C., Hardy C.,
RA   Jia M., Latimer C., Lau K.W., Marshall J., McLaren S., Menzies A.,
RA   Mudie L., Stebbings L., Largaespada D.A., Wessels L.F.A., Richard S.,
RA   Kahnoski R.J., Anema J., Tuveson D.A., Perez-Mancera P.A.,
RA   Mustonen V., Fischer A., Adams D.J., Rust A., Chan-On W., Subimerb C.,
RA   Dykema K., Furge K., Campbell P.J., Teh B.T., Stratton M.R.,
RA   Futreal P.A.;
RT   "Exome sequencing identifies frequent mutation of the SWI/SNF complex
RT   gene PBRM1 in renal carcinoma.";
RL   Nature 469:539-542(2011).
CC   -!- FUNCTION: As a component of the trimeric and tetrameric DNA
CC       polymerase delta complexes (Pol-delta3 and Pol-delta4,
CC       respectively), plays a role in high fidelity genome replication,
CC       including in lagging strand synthesis, and repair. Required for
CC       optimal Pol-delta activity. Stabilizes the Pol-delta complex and
CC       plays a major role in Pol-delta stimulation by PCNA
CC       (PubMed:10219083, PubMed:10852724, PubMed:11595739,
CC       PubMed:16510448, PubMed:24035200). Pol-delta3 and Pol-delta4 are
CC       characterized by the absence or the presence of POLD4. They
CC       exhibit differences in catalytic activity. Most notably, Pol-
CC       delta3 shows higher proofreading activity than Pol-delta4
CC       (PubMed:19074196, PubMed:20334433). Although both Pol-delta3 and
CC       Pol-delta4 process Okazaki fragments in vitro, Pol-delta3 may also
CC       be better suited to fulfill this task, exhibiting near-absence of
CC       strand displacement activity compared to Pol-delta4 and stalling
CC       on encounter with the 5'-blocking oligonucleotides. Pol-delta3
CC       idling process may avoid the formation of a gap, while maintaining
CC       a nick that can be readily ligated (PubMed:24035200). Along with
CC       DNA polymerase kappa, DNA polymerase delta carries out
CC       approximately half of nucleotide excision repair (NER) synthesis
CC       following UV irradiation. In this context, POLD3, along with PCNA
CC       and RFC1-replication factor C complex, is required to recruit
CC       POLD1, the catalytic subunit of the polymerase delta complex, to
CC       DNA damage sites (PubMed:20227374). Under conditions of DNA
CC       replication stress, required for the repair of broken replication
CC       forks through break-induced replication (BIR) (PubMed:24310611).
CC       Involved in the translesion synthesis (TLS) of templates carrying
CC       O6-methylguanine or abasic sites performed by Pol-delta4,
CC       independently of DNA polymerase zeta (REV3L) or eta (POLH).
CC       Facilitates abasic site bypass by DNA polymerase delta by
CC       promoting extension from the nucleotide inserted opposite the
CC       lesion (PubMed:19074196, PubMed:25628356, PubMed:27185888). Also
CC       involved in TLS, as a component of the POLZ complex. Along with
CC       POLD2, dramatically increases the efficiency and processivity of
CC       DNA synthesis of the minimal DNA polymerase zeta complex,
CC       consisting of only REV3L and REV7 (PubMed:24449906).
CC       {ECO:0000269|PubMed:10219083, ECO:0000269|PubMed:10852724,
CC       ECO:0000269|PubMed:11595739, ECO:0000269|PubMed:16510448,
CC       ECO:0000269|PubMed:19074196, ECO:0000269|PubMed:20227374,
CC       ECO:0000269|PubMed:20334433, ECO:0000269|PubMed:24035200,
CC       ECO:0000269|PubMed:24310611, ECO:0000269|PubMed:24449906,
CC       ECO:0000269|PubMed:25628356, ECO:0000269|PubMed:27185888}.
CC   -!- SUBUNIT: Component of the tetrameric DNA polymerase delta complex
CC       (Pol-delta4), which consists of POLD1/p125, POLD2/p50,
CC       POLD3/p66/p68 and POLD4/p12, with POLD1 bearing DNA polymerase and
CC       3' to 5' proofreading exonuclease activities (PubMed:11328591,
CC       PubMed:11595739, PubMed:17317665, PubMed:22801543). Within this
CC       complex, directly interacts with POLD2 (PubMed:11328591,
CC       PubMed:16510448, PubMed:18818516). Following stress caused by DNA
CC       damaging agents or by replication stress, POLD4 is degraded and
CC       Pol-delta4 is converted into a trimeric form of the complex (Pol-
CC       delta3), which consists of POLD1, POLD2 and POLD3. Pol-delta3 is
CC       the major form occurring at S phase replication sites, as well as
CC       DNA damage sites (PubMed:11595739, PubMed:17317665,
CC       PubMed:22801543, PubMed:23913683). Directly interacts with PCNA,
CC       as do POLD1 and POLD4; this interaction stimulates Pol-delta
CC       polymerase activity (PubMed:11328591, PubMed:11595739,
CC       PubMed:12403614, PubMed:16510448, PubMed:22148433). POLD3
CC       phosphorylation at Ser-458 impairs PCNA binding (PubMed:22148433).
CC       Component of the DNA polymerase zeta complex (POLZ), which
CC       consists of REV3L, MAD2L2, POLD2 and POLD3, with REV3L bearing DNA
CC       polymerase catalytic activity (PubMed:24449906). The DNA
CC       polymerase delta complex interacts with POLDIP2; this interaction
CC       is probably mediated through direct binding to POLD2
CC       (PubMed:12522211). {ECO:0000269|PubMed:11328591,
CC       ECO:0000269|PubMed:11595739, ECO:0000269|PubMed:12403614,
CC       ECO:0000269|PubMed:12522211, ECO:0000269|PubMed:16510448,
CC       ECO:0000269|PubMed:17317665, ECO:0000269|PubMed:18818516,
CC       ECO:0000269|PubMed:22148433, ECO:0000269|PubMed:22801543,
CC       ECO:0000269|PubMed:23913683, ECO:0000269|PubMed:24449906}.
CC   -!- INTERACTION:
CC       P12004:PCNA; NbExp=5; IntAct=EBI-864956, EBI-358311;
CC       P49005:POLD2; NbExp=5; IntAct=EBI-864956, EBI-372354;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:Q9EQ28}.
CC       Nucleus {ECO:0000269|PubMed:11595739, ECO:0000269|PubMed:20227374,
CC       ECO:0000269|PubMed:22801543}. Note=Partially colocalizes with PCNA
CC       and POLD1 at S phase replication sites (PubMed:11595739).
CC       Recruited to DNA damage sites within 2 hours following UV
CC       irradiation (PubMed:20227374, PubMed:22801543).
CC       {ECO:0000269|PubMed:11595739, ECO:0000269|PubMed:20227374,
CC       ECO:0000269|PubMed:22801543}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q15054-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q15054-2; Sequence=VSP_054150;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=Q15054-3; Sequence=VSP_054149;
CC         Note=No experimental confirmation available.;
CC   -!- DEVELOPMENTAL STAGE: Expression is cell cycle-dependent, with
CC       highest levels in G2/M phase and lowest in G1.
CC       {ECO:0000269|PubMed:22801543}.
CC   -!- PTM: Ubiquitinated, but not targeted to the proteasome
CC       (PubMed:16934752). Sumoylated (PubMed:16934752, PubMed:25218447).
CC       Sumoylation with SUMO3 may be predominant (PubMed:16934752).
CC       {ECO:0000269|PubMed:16934752, ECO:0000269|PubMed:25218447}.
CC   -!- PTM: Phosphorylation at Ser-458 is catalyzed in vitro by PKA. It
CC       is thought to decrease the affinity for PCNA and Pol-delta4
CC       processivity (PubMed:22148433). Can also be phosphorylated in
CC       vitro by CDK1-cyclin-A complex, as well as CDK2-cyclin-A and CDK2-
CC       cyclin-E complexes. PCNA interferes with CDK-cyclin
CC       phosphorylation (PubMed:11595739). {ECO:0000269|PubMed:11595739,
CC       ECO:0000269|PubMed:22148433}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA05039.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D26018; BAA05039.1; ALT_INIT; mRNA.
DR   EMBL; AK316301; BAH14672.1; -; mRNA.
DR   EMBL; AP001104; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP001324; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP001372; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471076; EAW74942.1; -; Genomic_DNA.
DR   EMBL; BC108908; AAI08909.1; -; mRNA.
DR   EMBL; BC108909; AAI08910.1; -; mRNA.
DR   CCDS; CCDS8233.1; -. [Q15054-1]
DR   RefSeq; NP_006582.1; NM_006591.2. [Q15054-1]
DR   UniGene; Hs.82502; -.
DR   PDB; 1U76; X-ray; 2.60 A; B/D/F=452-466.
DR   PDB; 2N1G; NMR; -; B=231-246.
DR   PDB; 3E0J; X-ray; 3.00 A; B/D/F/H=1-144.
DR   PDBsum; 1U76; -.
DR   PDBsum; 2N1G; -.
DR   PDBsum; 3E0J; -.
DR   ProteinModelPortal; Q15054; -.
DR   SMR; Q15054; -.
DR   BioGrid; 115940; 28.
DR   DIP; DIP-35772N; -.
DR   IntAct; Q15054; 8.
DR   MINT; MINT-2789689; -.
DR   STRING; 9606.ENSP00000263681; -.
DR   iPTMnet; Q15054; -.
DR   PhosphoSitePlus; Q15054; -.
DR   BioMuta; POLD3; -.
DR   DMDM; 17375506; -.
DR   EPD; Q15054; -.
DR   MaxQB; Q15054; -.
DR   PaxDb; Q15054; -.
DR   PeptideAtlas; Q15054; -.
DR   PRIDE; Q15054; -.
DR   Ensembl; ENST00000263681; ENSP00000263681; ENSG00000077514. [Q15054-1]
DR   Ensembl; ENST00000527458; ENSP00000432951; ENSG00000077514. [Q15054-2]
DR   Ensembl; ENST00000532497; ENSP00000436018; ENSG00000077514. [Q15054-3]
DR   GeneID; 10714; -.
DR   KEGG; hsa:10714; -.
DR   UCSC; uc001ovf.3; human. [Q15054-1]
DR   CTD; 10714; -.
DR   DisGeNET; 10714; -.
DR   GeneCards; POLD3; -.
DR   HGNC; HGNC:20932; POLD3.
DR   HPA; HPA058846; -.
DR   MalaCards; POLD3; -.
DR   MIM; 611415; gene.
DR   neXtProt; NX_Q15054; -.
DR   OpenTargets; ENSG00000077514; -.
DR   PharmGKB; PA134868595; -.
DR   eggNOG; ENOG410IGGV; Eukaryota.
DR   eggNOG; ENOG410XSD1; LUCA.
DR   GeneTree; ENSGT00390000015282; -.
DR   HOGENOM; HOG000008055; -.
DR   HOVERGEN; HBG051397; -.
DR   InParanoid; Q15054; -.
DR   KO; K03504; -.
DR   OMA; FSAIQCA; -.
DR   OrthoDB; EOG091G11SX; -.
DR   PhylomeDB; Q15054; -.
DR   TreeFam; TF103006; -.
DR   Reactome; R-HSA-110314; Recognition of DNA damage by PCNA-containing replication complex.
DR   Reactome; R-HSA-174411; Polymerase switching on the C-strand of the telomere.
DR   Reactome; R-HSA-174414; Processive synthesis on the C-strand of the telomere.
DR   Reactome; R-HSA-174417; Telomere C-strand (Lagging Strand) Synthesis.
DR   Reactome; R-HSA-174437; Removal of the Flap Intermediate from the C-strand.
DR   Reactome; R-HSA-5358565; Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha).
DR   Reactome; R-HSA-5358606; Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta).
DR   Reactome; R-HSA-5651801; PCNA-Dependent Long Patch Base Excision Repair.
DR   Reactome; R-HSA-5656169; Termination of translesion DNA synthesis.
DR   Reactome; R-HSA-5685942; HDR through Homologous Recombination (HRR).
DR   Reactome; R-HSA-5696397; Gap-filling DNA repair synthesis and ligation in GG-NER.
DR   Reactome; R-HSA-5696400; Dual Incision in GG-NER.
DR   Reactome; R-HSA-6782135; Dual incision in TC-NER.
DR   Reactome; R-HSA-6782210; Gap-filling DNA repair synthesis and ligation in TC-NER.
DR   Reactome; R-HSA-69091; Polymerase switching.
DR   Reactome; R-HSA-69166; Removal of the Flap Intermediate.
DR   Reactome; R-HSA-69183; Processive synthesis on the lagging strand.
DR   SIGNOR; Q15054; -.
DR   EvolutionaryTrace; Q15054; -.
DR   GeneWiki; POLD3; -.
DR   GenomeRNAi; 10714; -.
DR   PRO; PR:Q15054; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000077514; -.
DR   ExpressionAtlas; Q15054; baseline and differential.
DR   Genevisible; Q15054; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0043625; C:delta DNA polymerase complex; NAS:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:HPA.
DR   GO; GO:0003887; F:DNA-directed DNA polymerase activity; TAS:Reactome.
DR   GO; GO:0042769; P:DNA damage response, detection of DNA damage; TAS:Reactome.
DR   GO; GO:0006266; P:DNA ligation; TAS:Reactome.
DR   GO; GO:0000731; P:DNA synthesis involved in DNA repair; NAS:UniProtKB.
DR   GO; GO:0006261; P:DNA-dependent DNA replication; IEA:Ensembl.
DR   GO; GO:0006298; P:mismatch repair; TAS:Reactome.
DR   GO; GO:0006297; P:nucleotide-excision repair, DNA gap filling; IMP:UniProtKB.
DR   GO; GO:0033683; P:nucleotide-excision repair, DNA incision; TAS:Reactome.
DR   GO; GO:0006296; P:nucleotide-excision repair, DNA incision, 5'-to lesion; TAS:Reactome.
DR   GO; GO:0000723; P:telomere maintenance; TAS:Reactome.
DR   GO; GO:0000722; P:telomere maintenance via recombination; TAS:Reactome.
DR   GO; GO:0006283; P:transcription-coupled nucleotide-excision repair; TAS:Reactome.
DR   GO; GO:0019985; P:translesion synthesis; TAS:Reactome.
DR   InterPro; IPR019038; DNA_polymerase_subunit_Cdc27.
DR   PANTHER; PTHR17598; PTHR17598; 1.
DR   Pfam; PF09507; CDC27; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Complete proteome;
KW   Cytoplasm; Direct protein sequencing; DNA damage; DNA excision;
KW   DNA repair; DNA replication; Isopeptide bond; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Ubl conjugation.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:22223895,
FT                                ECO:0000269|Ref.6}.
FT   CHAIN         2    466       DNA polymerase delta subunit 3.
FT                                /FTId=PRO_0000186047.
FT   REGION      456    466       Interaction with PCNA.
FT                                {ECO:0000269|PubMed:11595739,
FT                                ECO:0000269|PubMed:22148433}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:22223895,
FT                                ECO:0000269|Ref.6}.
FT   MOD_RES     277    277       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     307    307       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     407    407       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     409    409       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     411    411       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     413    413       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     458    458       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:22148433}.
FT   CROSSLNK    258    258       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000244|PubMed:25218447,
FT                                ECO:0000269|PubMed:16934752}.
FT   CROSSLNK    433    433       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000269|PubMed:16934752}.
FT   VAR_SEQ       1    106       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_054149.
FT   VAR_SEQ       1     39       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_054150.
FT   VARIANT     194    194       G -> V (found in a renal cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:21248752}.
FT                                /FTId=VAR_064745.
FT   VARIANT     195    195       M -> L (found in a renal cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:21248752}.
FT                                /FTId=VAR_064746.
FT   MUTAGEN     258    258       K->R: Partially loss of sumoylation.
FT                                Complete loss of sumoylation; when
FT                                associated with R-433.
FT                                {ECO:0000269|PubMed:16934752}.
FT   MUTAGEN     325    325       K->R: No effect on sumoylation.
FT                                {ECO:0000269|PubMed:16934752}.
FT   MUTAGEN     433    433       K->R: Partially loss of sumoylation.
FT                                Complete loss of SUMO3-sumoylation; when
FT                                associated with R-285.
FT                                {ECO:0000269|PubMed:16934752}.
FT   MUTAGEN     456    466       Missing: Complete loss of PCNA binding.
FT                                {ECO:0000269|PubMed:22148433}.
FT   MUTAGEN     458    458       S->A: Partial loss of PCNA binding (60%
FT                                of wild-type) and strong decrease of PCNA
FT                                stimulation of Pol-delta4 polymerase
FT                                activity. {ECO:0000269|PubMed:22148433}.
FT   MUTAGEN     459    463       ITGFF->ATGAA: Complete loss of PCNA
FT                                binding. {ECO:0000269|PubMed:22148433}.
FT   HELIX         3     14       {ECO:0000244|PDB:3E0J}.
FT   TURN         15     17       {ECO:0000244|PDB:3E0J}.
FT   HELIX        23     30       {ECO:0000244|PDB:3E0J}.
FT   HELIX        34     52       {ECO:0000244|PDB:3E0J}.
FT   STRAND       58     81       {ECO:0000244|PDB:3E0J}.
FT   TURN         82     84       {ECO:0000244|PDB:3E0J}.
FT   HELIX        85     91       {ECO:0000244|PDB:3E0J}.
FT   STRAND       93    106       {ECO:0000244|PDB:3E0J}.
FT   STRAND      109    111       {ECO:0000244|PDB:3E0J}.
FT   HELIX       113    125       {ECO:0000244|PDB:3E0J}.
FT   HELIX       129    131       {ECO:0000244|PDB:3E0J}.
FT   STRAND      134    136       {ECO:0000244|PDB:3E0J}.
FT   STRAND      238    244       {ECO:0000244|PDB:2N1G}.
FT   HELIX       459    461       {ECO:0000244|PDB:1U76}.
SQ   SEQUENCE   466 AA;  51400 MW;  E9625E0188725F45 CRC64;
     MADQLYLENI DEFVTDQNKI VTYKWLSYTL GVHVNQAKQM LYDYVERKRK ENSGAQLHVT
     YLVSGSLIQN GHSCHKVAVV REDKLEAVKS KLAVTASIHV YSIQKAMLKD SGPLFNTDYD
     ILKSNLQNCS KFSAIQCAAA VPRAPAESSS SSKKFEQSHL HMSSETQANN ELTTNGHGPP
     ASKQVSQQPK GIMGMFASKA AAKTQETNKE TKTEAKEVTN ASAAGNKAPG KGNMMSNFFG
     KAAMNKFKVN LDSEQAVKEE KIVEQPTVSV TEPKLATPAG LKKSSKKAEP VKVLQKEKKR
     GKRVALSDDE TKETENMRKK RRRIKLPESD SSEDEVFPDS PGAYEAESPS PPPPPSPPLE
     PVPKTEPEPP SVKSSSGENK RKRKRVLKSK TYLDGEGCIV TEKVYESESC TDSEEELNMK
     TSSVHRPPAM TVKKEPREER KGPKKGTAAL GKANRQVSIT GFFQRK
//
